First report of BCL-2 inhibitor TQB3909 in pts with relapsed or refractory non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML): Data from a phase I study

被引：1
|
作者：
Qi, J. [1 ]
Li, J. [2 ,9 ]
Xu, W. [2 ]
Zhao, X. [3 ]
Yin, Q. [4 ]
Li, Y. [5 ,6 ]
Xu, F. [7 ]
Huang, H. [8 ]
Li, J. [2 ,9 ]
Qian, W. [10 ]
Zhao, Q. [11 ]
Wang, J. [12 ]
机构：
[1] Chinese Acad Med Sci, Inst Hematol & Blood Dis Hosp, IGCP Ctr Stage Ward, Tianjin, Peoples R China
[2] Nanjing Med Univ, Dept Hematol, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Peoples R China
[3] Tianjin Peoples Hosp, Dept Hematol, Tianjin, Peoples R China
[4] Zhengzhou Univ, Dept Hematol, Henan Canc Hospital, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[5] Hunan Canc Hosp, Dept Lymphoma & Hemato, Changsha, Peoples R China
[6] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China
[7] Mianyang Cent Hosp, Dept Hematol, Mianyang, Peoples R China
[8] Sun Yat Sen Univ, Dept Gynecol Oncol, Canc Ctr, Guangzhou, Peoples R China
[9] Shandong Univ, Dept Hematol, Qilu Hosp, Jinan, Peoples R China
[10] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Med Sch, Hangzhou, Peoples R China
[11] CTTQ Chia Tai Tianqing Pharmaceut Grp Co Ltd, Nanjing Site, Clin Med, Nanjing, Peoples R China
[12] Chinese Acad Med Sci Peking Union Med Coll, Inst Hematol & Blood Hosp, Leukemia Ctr, Tianjin, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.851
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
800MO
引用
收藏
页码：S596 / S596
页数：1
相关论文
共 50 条
  • [21] A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenstrom Macroglobulinemia (WM): Preliminary Data
    Soumerai, Jacob D.
    Lasica, Masa
    Opat, Stephen
    Cheah, Chan Y.
    Chan, Henry
    Verner, Emma
    Barca, Eva Gonzalez
    Tedeschi, Alessandra
    Hilger, James
    Fang, Yiqian
    Simpson, David
    Tam, Constantine S.
    BLOOD, 2022, 140 : 9325 - 9327
  • [22] Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
    Kevin R. Kelly
    Thomas C. Shea
    André Goy
    Jesus G. Berdeja
    Craig B. Reeder
    Kevin T. McDonagh
    Xiaofei Zhou
    Hadi Danaee
    Hua Liu
    Jeffrey A. Ecsedy
    Huifeng Niu
    Ely Benaim
    Swaminathan Padmanabhan Iyer
    Investigational New Drugs, 2014, 32 : 489 - 499
  • [23] The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
    de Vos, Sven
    Flowers, Christopher R.
    Wang, Ding
    Swinnen, Lode J.
    Fowler, Nathan
    Reid, Erin
    Gifford, Maryella
    D'Amico, Diane
    Dunbar, Martin
    Zhu, Ming
    Yang, Jianning
    Enschede, Sari H.
    Ricker, Justin L.
    Chien, David
    Humerickhouse, Rod A.
    Kozloff, Mark
    BLOOD, 2014, 124 (21)
  • [24] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
    DeRook, Ian
    Odonnell, Robert T.
    Noble, B.
    Quirch, C.
    Tuscano, Joseph
    BLOOD, 2008, 112 (11) : 1052 - 1052
  • [25] Phase I study of CC-90011 in patients with advanced solid tumours (STs) and relapsed/refractory non-hodgkin lymphoma (R/R NHL)
    Hollebecque, A.
    de Bono, J. S.
    Salvagni, S.
    Plummer, R.
    Isambert, N.
    Niccoli, P.
    Capdevila, J.
    Curigliano, G.
    Moreno, V.
    De Braud, F. G. M.
    Lopez-Brea, M.
    Martin-Romano, P.
    Baudin, E.
    Arias, M.
    de Alvaro, J.
    Parra-Palau, J.
    Sanchez Perez, T.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed Refractory Indolent Non-Hodgkin's Lymphoma (NHL).
    Dutia, Mrinal
    DeRoock, Ian
    Chee, Karen
    O'donnell, Robert
    Quirch, Christine
    Reed-Pease, Christine
    Tuscano, Joseph
    BLOOD, 2009, 114 (22) : 670 - 670
  • [27] Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin's Lymphoma (NHL)
    De Vos, Sven
    Flowers, Christopher
    Wang, Ding
    Swinnen, Lode J.
    Fowler, Nathan Hale
    Reid, Erin G.
    Cordero, Jaclyn
    Gifford, Maryella
    D'Amico, Diane
    Dunbar, Martin
    Zhu, Ming
    Salem, Ahmed H.
    Enschede, Sari H.
    Ricker, Justin L.
    Chien, David
    Humerickhouse, Rod
    Kozloff, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
    Waters, JS
    Webb, A
    Cunningham, D
    Clarke, PA
    Raynaud, F
    di Stefano, F
    Cotter, FE
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (09) : 1812 - 1823
  • [29] A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).
    Ando, Kiyoshi
    Ogura, Michinori
    Suzuki, Tatsuya
    Ishizawa, Kenichi
    Oh, Sung Yong
    Kim, Won Seog
    Tanaka, Yoshinobu
    Shimamoto, Takashi
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
    Hollebecque, A.
    de Bono, J. S.
    Salvagni, S.
    Plummer, R.
    Niccoli, P.
    Capdevila, J.
    Curigliano, G.
    Moreno, V.
    De Braud, F.
    Gonzalez de Villambrosia, S.
    Martin-Romano, P.
    Baudin, E.
    Arias, M.
    De Alvaro, J.
    Parra-Palau, J.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S4 - S4
12345